article thumbnail

Revolution Medicines files patent for inhibiting RAS proteins for cancer treatment

Pharmaceutical Technology

Discover how Revolution Medicines Inc. is revolutionizing cancer treatment with their patented macrocyclic compounds targeting Ras proteins. Learn more about their potential impact on various types of cancer and Ras mutations.

Protein 100
article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Touting a new way to drug an all-important family of proteins, a startup launches with $100M

Bio Pharma Dive

Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.

Protein 312
article thumbnail

FDA approves new ALS medicine in precedent-setting decision

Bio Pharma Dive

Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.

article thumbnail

With $81M, Entact Bio takes a new approach to fixing helpful proteins

Bio Pharma Dive

Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.

Protein 204
article thumbnail

Key Parkinson’s protein could offer new potential targets for treatment

Pharma Times

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 108
article thumbnail

Regenerative medicine: new focus on VEGF target?

Pharmaceutical Technology

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

Medicine 246